Pipeline
One asset, a path across CNS oncology.
LMP01, our lead program, is a small molecule combination delivered intranasally, designed to reach the brain directly and to act on two pathways tumors depend on to grow. After establishing proof of concept in glioblastoma, we plan to explore other CNS cancers where direct brain delivery matters most.
LMP01
Newly diagnosed IDH wild-type glioblastoma
Planned, following recurrent glioblastoma
Potential expansion indications
Not yet studied. To be prioritized as data from our glioblastoma program mature.
- Recurrent high-grade gliomasNon-GBM
- Brain metastases
- Leptomeningeal disease
- Primary CNS lymphoma
- Pediatric high-grade gliomas
One asset, a path across CNS oncology
Each expansion indication would use the same combination, the same intranasal route and the same manufacturing process as our lead program. That would let us grow through new studies and label extensions rather than building a new drug for every disease.
The pathways LMP01 targets are not unique to glioblastoma, and the blood-brain barrier limits treatment across all of these cancers. We will decide which indications to pursue, and in what order, based on what our data show.
Expansion indications are potential future programs and are subject to supporting preclinical data. Development timelines may change.